{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:30:44Z","timestamp":1784863844591,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Kalbe Farma"},{"name":"KalgenDNA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clml.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T22:42:55Z","timestamp":1547851375000},"page":"220-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB)"],"prefix":"10.1016","volume":"19","author":[{"given":"Najmiatul","family":"Masykura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummu","family":"Habibah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Fatimah","family":"Selasih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soegiarto","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosphiadi","family":"Irawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugiyono","family":"Somoastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Rusdan","family":"Handoyo Utomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.01.005_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.01.005_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A\u00a0multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.01.005_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4065\/80.3.390","article-title":"Chronic myeloid leukemia: Current application of cytogenetics and molecular testing for diagnosis and treatment","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2019.01.005_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.01.005_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018","volume":"15","author":"Mesa","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.01.005_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2019.01.005_bib7","doi-asserted-by":"crossref","first-page":"e86401","DOI":"10.1371\/journal.pone.0086401","article-title":"Improved diagnosis of the transition to JAK2V617F homozygosity: The key feature for predicting the evolution of myeloproliferative neoplasms","volume":"9","author":"Gonzalez","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.01.005_bib8","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1093\/nar\/19.14.3929","article-title":"Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonucleotides","volume":"19","author":"Zhang","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clml.2019.01.005_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.01.005_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jmoldx.2012.04.003","article-title":"Genotyping of chimerical BCR-ABL1 RNA in chronic myeloid leukemia by integrated DNA chip","volume":"14","author":"Kang","year":"2012","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2019.01.005_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/sj.leu.2404987","article-title":"Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform","volume":"22","author":"Corradi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.01.005_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2010.090068","article-title":"Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory","volume":"12","author":"Merker","year":"2010","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2019.01.005_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bjhh.2014.08.003","article-title":"Is the BCR-ABL\/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?","volume":"37","author":"Bonecker","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.clml.2019.01.005_bib14","doi-asserted-by":"crossref","first-page":"e106250","DOI":"10.1371\/journal.pone.0106250","article-title":"Major molecular response achievement in CML patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended","volume":"9","author":"Huet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.01.005_bib15","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.01.005_bib16","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.01.005_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620716657994","article-title":"Current developments in molecular monitoring in chronic myeloid leukemia","volume":"7","author":"Marum","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2019.01.005_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.leukres.2013.11.016","article-title":"Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response","volume":"38","author":"O'Dwyer","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.01.005_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/PAT.0000000000000293","article-title":"A\u00a0longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system","volume":"47","author":"Enjeti","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2019.01.005_bib20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.clml.2019.01.005_bib21","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.01.005_bib22","first-page":"130","article-title":"Clinical applications of molecular technologies in hematology","volume":"2","author":"Lam","year":"2013","journal-title":"J\u00a0Med Diagn Methods"},{"key":"10.1016\/j.clml.2019.01.005_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.plabm.2015.12.004","article-title":"Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms","volume":"4","author":"Didone","year":"2015","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.clml.2019.01.005_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"Bench","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.01.005_bib25","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/bcj.2015.77","article-title":"Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib","volume":"5","author":"Zhou","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.01.005_bib26","first-page":"116","article-title":"Detection of Jak2 V617f mutation, secondary to the presence of Bcr-Abl1 translocation in a patient with chronic myeloid leukemia: report of a case and review of the literature","volume":"2","author":"Carranza","year":"2014","journal-title":"Int J Genomic Med"},{"key":"10.1016\/j.clml.2019.01.005_bib27","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.leu.2405088","article-title":"JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: One patient with two distinct myeloproliferative disorders","volume":"22","author":"Cambier","year":"2008","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.01.005_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12288-014-0385-1","article-title":"Coexistence of JAK2V617F mutation and BCR\u2013ABL translocation in a pregnant woman with essential thrombocythemia","volume":"30","author":"Qin","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2019.01.005_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","article-title":"Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.01.005_bib30","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/blood-2011-07-365007","article-title":"Concomitant occurrence of BCR-ABL and JAK2V617F mutation","volume":"118","author":"Pieri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.01.005_bib31","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1182\/blood.V120.21.1766.1766","article-title":"High frequency of concurrent JAK2 V617F mutation and BCR\/ABL fusion gene in a cohort (18\/142) of Mexican patients with MPD","volume":"120","author":"Trejo","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.01.005_bib32","first-page":"185","article-title":"Frequency of JAK2 V617F mutation in patients with Philadelphia positive chronic myeloid leukemia in Pakistan","volume":"30","author":"Tabassum","year":"2014","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.clml.2019.01.005_bib33","first-page":"131","article-title":"BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance","volume":"176","author":"Martin-Cabrera","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.01.005_bib34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","article-title":"Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the association for molecular pathology","volume":"15","author":"Gong","year":"2013","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2019.01.005_bib35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2009.149","article-title":"Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics","volume":"6","author":"Tefferi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2019.01.005_bib36","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2012.47.8669","article-title":"Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone","volume":"32","author":"Yamada","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.01.005_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2162-3619-2-24","article-title":"Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F","volume":"2","author":"Pastore","year":"2013","journal-title":"Exp Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:07Z","timestamp":1761870727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018316008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2152265018316008"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.01.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}